Navigation Links
ZyGEM and Advalytix Partner to Produce Innovative DNA Extraction Products

-New Collaboration Brings ZyGEM's Unique Temperature-Controlled DNA Extraction Technology to Advalytix Customers as Private-Label Kits-

SOLANA BEACH, Calif. and HAMILTON, New Zealand and MUNICH, Germany, Oct. 16 /PRNewswire/ -- ZyGEM Corp. Ltd. today announced that it has entered into an agreement with the Advalytix product team of Olympus Life Science Research Europa GmbH to produce a private-label line of DNA extraction products. The collaboration will combine ZyGEM's advanced enzymatic nucleic acid extraction technology and Advalytix's expertise in single-cell molecular tests for life science research and diagnostic applications.

ZyGEM's DNA extraction technology uses a proprietary thermophilic enzyme to extract DNA from samples using a single closed-tube system. ZyGEM's approach simplifies laboratory workflow, minimises error, reduces the risk of contamination and ensures sample integrity, while also reducing costs. The technology can be specifically formulated for use with a wide range of different sample types without the need for further purification. ZyGEM's technology has been validated for use in research, forensic, diagnostic, agriculture and animal health applications.

"ZyGEM's unique temperature-controlled DNA extraction technology provides important advantages that are especially relevant as demand for DNA analysis continues to increase, and we are delighted to partner with an innovative group such as Advalytix to make our technology available to more users," said Paul Kinnon, CEO of ZyGEM. "This new agreement for private-label DNA extraction products is the most recent in a series of ZyGEM collaborations with diverse partners to ensure wide availability of our versatile technology, and we look forward to a mutually productive relationship with Advalytix."

Advalytix will market private-label DNA extraction products based on ZyGEM's temperature-controlled extraction (TEC) technology. The kits are designed to work with Advalytix's single-cell molecular diagnostics and its miniaturised diagnostic and biological tests for research and development. Advalytix is Olympus' division focusing on cell-based molecular biology. Advalytix's products uniquely link imaging technologies such as microscopy with nucleic acid analysis, enabling fully integrated solutions with optimised instruments and reagents.

"We are committed to providing our customers with innovative technology that enables them to conduct analyses and experiments more simply, rapidly, accurately and cost effectively, and we believe that access to ZyGEM's distinctive temperature-controlled nucleic acid extraction technology will help advance that goal," said Frank Feist, executive director of the Advalytix business, Olympus America. "We look forward to offering private-label DNA extraction products based on the ZyGEM technology to our growing customer base."

Terms of the agreement were not disclosed.

About ZyGEM Corporation

ZyGEM Corporation Limited is a rapidly growing biotechnology company with a range of innovative enzyme-based products and technologies based on the company's exclusive collection of microorganisms from extreme environments. ZyGEM's technology has significant competitive advantages over existing methods and has potential applications in a number of sizeable global markets. ZyGEM currently produces DNA extraction and detection products, molecular biology enzymes and individual enzymes and diagnostics, serving life sciences customers in basic research, forensics, clinical diagnostics and agriculture. ZyGEM has facilities in New Zealand and the U.S.A. For more information, visit

About Advalytix

Advalytix is Olympus' worldwide competence centre for cell-based molecular biology, with a focus on single-cell molecular diagnostics and the miniaturisation of diagnostic and biological tests for research and development. Advalytix products uniquely link imaging technologies such as microscopy with nucleic acid analysis, enabling turnkey solutions with optimised instruments and reagents.


ZyGEM Advalytix

Corporate: Media: Corporate/Media:

Paul Kinnon Barbara Lindheim Frank Feist

President and CEO BioCom Partners Executive Director Advalytix

858-720-8333 212-918-4650 (987)405-2533

SOURCE ZyGEM Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
2. ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon
5. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
6. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
9. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
11. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
Post Your Comments:
(Date:10/13/2015)... NC (PRWEB) , ... October 13, 2015 , ... ... intensity focused ultrasound (HIFU) technologies, announced today that it received de novo clearance ... in the U.S. for the ablation of prostate tissue. Sonablate® is the ...
(Date:10/12/2015)... BRUSSELS , Oct. 12, 2015  Amgen ... presented additional findings from an exploratory sub-study of the previously ... presented today in an oral plenary session at the American ... in Seattle . 2 ... The small exploratory sub-study data showed that, at month 12, ...
(Date:10/12/2015)... Oct. 12, 2015  Rebiotix Inc. today announced ... designated its lead Microbiota Restoration Therapy (MRT) RBX2660 ... recurrent Clostridium difficile (C diff) infection, ... causes 29,000 deaths in the U.S. annually. 1 ... that was founded to revolutionize the treatment of ...
(Date:10/12/2015)... , Oct. 12, 2015  Patara Pharma, ... allergic and inflammatory diseases and conditions, today announced ... preferred stock financing. Concurrent with the close of ... into a Loan and Security Agreement with Silicon ... to $7 million. Patara will use the funds ...
Breaking Biology Technology:
(Date:10/9/2015)... 09 2015 ... the "Samsung Galaxy S6 Fingerprint Sensor ... their offering. --> ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> Research and Markets ( ...
(Date:10/8/2015)... OXFORD, Connecticut , October 8, 2015 /PRNewswire/ ... ) ("NXT-ID" or the "Company"), a biometric authentication ... and creator of the Wocket® smart wallet announces ... 30, 2015 were approximately $410,000 compared with $113,00 ... Revenues for the 9 months ended September 30, ...
(Date:10/6/2015)... 6, 2015 Track Group, Inc. (OTCQX: TRCK), ... has signed a contract with the Virginia Department of ... range of sentences under the Department,s oversight. ... "This contract with the Virginia DOC will expand our ... advances our position as a trusted leader in offender ...
Breaking Biology News(10 mins):